other IDO1-targeting approaches, as well as decoding the underlying mechanism of cooperativity between anti-PD-1 antibody and IDO1 peptide vaccines.

REFERENCE


PO4.04 MULTIFUNCTIONAL ANTIBODY CONSTRUCT FOR IN VIVO TARGETING OF DENDRITIC CELLS AS A THERAPEUTIC VACCINATION STRATEGY IN AML

1S Schmitt*, 2,3A Lohner, 2,3K Deiser, 2A Maiser, 2,3M Roth, 2,3C Augsberger, 1A Moosmann, 1H Leonhardt, 1N Fenn, 4M Griffioen, 2,3K Hopfer, 2,3M Subklewe.

1Department of Biochemistry, Gene Center of the LMU Munich, Munich, Germany; 2Department of Medicine III, University Hospital, LMU Munich, Munich, Germany; 3Laboratory for Translational Cancer Immunology, Gene Center of the LMU Munich, Munich, Munich, Germany; 4Department of Biology II, Center for Integrated Protein Science Munich, Munich, Germany; Research Unit Gene Vectors, Haematologikum, Helmholtz Center Munich, Munich, Germany; 6Department of Hematology, Leiden University Medical Center, Leiden, Netherlands; 7German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany

Background Dendritic cells (DCs) are antigen-presenting cells that induce antigen-specific T-cell responses. Therefore, they are used as tools and targets for anti-tumor vaccination. In contrast to T-cell based immunotherapies, that are often limited to surface antigens, DC-based vaccination strategies open up new therapeutic options by utilizing highly abundant intracellular tumor antigens as a target source. Among those, recent interest has been focused on the identification of neo-antigens derived from tumor-specific mutations. Especially mutated Nucleophosmin 1 (NPM1) is a candidate antigen for targeted therapy in acute myeloid leukemia (AML). We developed a multifunctional antibody construct consisting of a peptide domain including a variable T-cell epitope that is fused to an αCD40 single chain variable fragment (scFv) with agonistic function to target and activate dendritic cells in vivo. To potentiate therapeutic efficacy, toll-like receptor (TLR) agonists can be attached as co-stimulatory domains, thereby aiming to enhance cross-presentation of conjugated (neo)antigens to CD8+ T cells.

Materials and Methods Flow cytometry and microscopy-based binding and internalization experiments were performed using monocyste-derived dendritic cells (moDCs). Uptregulation of surface markers (CD80, CD83, CD86, HLA-DR) as well as cytokine secretion (IL-6 and IL-12) indicated DC maturation. To validate peptide processing and presentation, moDCs were co-cultured with autologous as well as allogeneic T cells. IFN-γ and TNF-α secretion served as a readout for T-cell activation, peptide-MHC multimer staining for T-cell proliferation.

Results For proof-of-principle experiments, the multispecific antibody derivative was developed by fusing the αCD40 scFv to a cytomegalovirus (CMV)-specific peptide. The αCD40.CMV construct bound CD40 agonistically and showed efficient internalization into early endosomal compartments on immature moDCs. In co-cultures of immature and mature moDCs with autologous or allogeneic T cells, αCD40.CMV induced a significantly increased T-cell activation and proliferation compared to the control. The control administration of αCD40.CMV with various TLR agonists as vaccine adjuvants resulted in a significant upregulation of DC maturation markers in comparison to αCD40.CMV only. Interestingly, not all adjuvants were able to enhance the T-cell response. To translate this principle to the AML setting, the CMV peptide sequence was replaced with the NPM1-targeted and HLA-A*02:01-binding neoadenyl CLAVEEVL. Cross-presentation to CD8+ T cells transduced with a NPM1-specific T-cell receptor was proven by IFN-γ and TNF-α secretion in co-cultures with moDCs that have been pre-incubated with αCD40.NPM1. The optimal vaccine adjuvant has yet to be identified.

Conclusions We successfully demonstrated the development of a multifunctional antibody construct that specifically targets and stimulates DC’s by an agonistic αCD40 scFv. It simultaneously delivers a T-cell-specific peptide with a vaccine adjuvant to induce an efficient T-cell response. As neoantigens are promising targets and under intense investigation, the αCD40.NPM1 fusion protein is of high therapeutic interest. Thus, our approach displays a promising DC vaccination option for the treatment of AML.


PO4.05 MODULATING TUMOR MICROENVIRONMENT WITH ARGINASE-1 SPECIFIC T CELLS

1E Martinenaita*, 2M Aaboe Joergensen, 3RE Johansson Mortensen, 2S Munir Ahmad, 2SE Weiis-Banke, 4M Orebo Holmström, 5A Waikatsuki Pedersen, 6O Met, 7M Swane, 2M Hald Andersen, 8IO Biotech, Copenhagen, Denmark; 9National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

Background Cancer progression is associated with an increased immune suppression at the tumor site. Arginase-1 is an enzyme well-known for its involvement in metabolic immune regulation. At the tumor site, arginase-1 acts by reducing availability of L-arginine to the infiltrating immune cells thus reducing T-cell functionality and proliferation. While arginase-1 is expressed by some tumor cells, it has also been shown to be produced by immune inhibitory myeloid cells, such as myeloid derived suppressor cells (MDSCs), tumor associated macrophages (TAMs) and is associated with poor prognosis. Previously, we demonstrated that spontaneous CD4+ and CD8+ T-cell immune responses against arginase-derived, HLA-restricted peptides can be found in both cancer patients and healthy individuals (Martinenaita et al., 2018, DOI: 10.1080/2162402X.2017.1404215). These T cells are present in the memory T cell compartment, and they are activated in arginase-1 inducing conditions,
such as presence of T_h2 cytokines IL-4 or IL-13 in vitro (Martinenaite et al, 2019, DOI: 10.1038/s41423-019-0231-3 and DOI: 10.11077/s00262-019-02425-6).

Methods and Results In order to explore if arginase-1-specific T cells have a potential role in modulation of immune homeostasis, human arginase-1-specific memory T cells were isolated and expanded for functional characterization. We show that arginase-1-specific T cells specifically recognize arginase-1 expressing cells, such as mRNA transfected autologous dendritic cells (DCs) and B cells as well as M2 polarized macrophages in vitro. In addition, activated arginase-1-specific T cells produce pro-inflammatory cytokines IFNγ and TNFα. Secretion of TH1 cytokines by these T cells suggests potential role as potent immune modulators in the tumor microenvironment, since many arginase-1 expressing myeloid cells are not terminally differentiated and they can be re-polarized to an immunostimulatory, M1-like phenotype. We also observed that targeting of M2-polarized arginase-1 expressing monocytic leukemia cell line THP-1 with arginase-1-specific CD4+ T cells induces upregulation of PD-L1 on the THP-1 cells. Furthermore, we demonstrate that an arginase-1-derive peptide vaccine has a therapeutic effect in syngeneic mouse tumor models (B16 and MC38), both as monotherapy and in combination with anti-PD-1 treatment. The therapeutic effect was associated with increased immune infiltration in the peptide vaccinated mice compared to the control.

Conclusions Our study provides evidence that immune modulatory vaccination targeting arginase-1 is an intriguing way of targeting the immune suppressive microenvironment.


P04.07 ABSTRACT WITHDRAWN

P04.08 VIRUS LIKE VACCINES: A NOVEL IMMUNOTHERAPY STRATEGY AGAINST THE CANCER-ASSOCIATED ENDOGENOUS RETROVIRUS

In face of the necessity of broadly acting and highly effective vaccines capable of eliminating/preventing human cancers with insufficient mutated antigens, we introduced the concept of Virus-Like Vaccines (VLVs). This strategy combines a replication-deficient retrovirus encoding virus structural proteins. These proteins assemble into secreted virus-like particles (VLPs) that deliver the target antigen to the immune system rising both humoral and cellular immune responses. Here, we use an adenoviral vector encoding the group specific antigen (Gag) and the glycoprotein of the viral envelope (Env) from endogenous retrovirus (ERV). Since ERV Env is reported to have immunosuppressive properties that support tumor establishment and development, we designed a modified vaccine that includes a mutation on the Env immunosuppressive domain (ISD) that